Bio-Techne Corporation (TECH)
收市後：
| 前收市價 | 69.92 |
| 開市 | 69.93 |
| 買盤 | 67.74 x 800 |
| 賣出價 | 71.11 x 800 |
| 今日波幅 | 69.20 - 70.12 |
| 52 週波幅 | 68.00 - 90.63 |
| 成交量 | |
| 平均成交量 | 807,898 |
| 市值 | 10.974B |
| Beta 值 (5 年，每月) | 1.21 |
| 市盈率 (最近 12 個月) | 39.40 |
| 每股盈利 (最近 12 個月) | 1.76 |
| 業績公佈日 | 2023年10月30日 - 2023年11月03日 |
| 遠期股息及收益率 | 0.32 (0.46%) |
| 除息日 | 2023年8月17日 |
| 1 年預測目標價 | 102.00 |
InvestorPlace3 Biotech Stocks to Buy Before the Breakout
During this Q3 of 2023, there have been many changes to U.S. healthcare at different levels. At the state level, there were changes to gender-affirming care. At the national level, the FDA has approved over-the-counter birth control pills and considered aspartame to be a carcinogen. The user count of telemedicine services continues to increase, and technological advancements in drug-making have led to the clinically testing a drug created by Artificial Intelligence in Hong Kong. These developmen
BenzingaBio-Techne's Acquisition of Lunaphore Expands Its Spatial Biology Offerings
Bio-Techne Corporation (NASDAQ: TECH) has agreed to acquire Lunaphore Inc with undisclosed deal terms. Lunaphore, founded in 2014 and based in Tolochenaz, Switzerland, develops fully automated spatial biology solutions using precision microfluidic technology. Lunaphore's instrument portfolio includes the COMET platform, offering automation, scalability, reproducibility, and tissue morphology analysis. The COMET platform allows researchers to leverage existing antibody libraries for multiplexing
Insider MonkeyShould You Hold Bio-Techne Corp. (TECH)?
Conestoga Capital Advisors, an asset management company, released its “Mid Cap Strategy” first-quarter 2023 investor letter. A copy of the same can be downloaded here. The Mid Cap Composite rose 10.23% net of fees in the first quarter, compared to the Russell Midcap Growth Index’s 9.14% return. The strategy primarily benefitted from the stock selection while the […]
